Gut Microbiota Dysbiosis and Translocation During IBD and Parkinson

Gut Microbiota Dysbiosis and Translocation Within Patients Suffering From Diseases Associated With Increased Intestinal Barrier Permeability : IBD and Parkinson

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT04159727

Acronym

Medibiote1

Enrollment

Registered

2019-11-12

Start date

2019-03-28

Completion date

2020-02-13

Last updated

2025-09-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Inflammatory Bowel Diseases, Parkinson Disease

Keywords

gut microbiota, Bacterial translocation

Brief summary

Inflammatory bowel diseases (IBD) and Parkinson disease (PD) are complex and multifactorial pathologies. Gut microbiota seems to play an active role. Indeed the digestive microbiota of patients with IBD or PD exhibits different compositions compared with asymptomatic subjects. Bacterial translocation from gut to blood has been reported.

Detailed description

The investigators designed a case-control study to investigate the digestive microbiota and bacterial translocation during IBD and PD. The investigators want to evaluate gut microbiota bacteria involved in dysbiosis and bacterial translocation during IBD and PD. The investigators want to identify bacterial populations that can serve as biomarkers for clinical practice.

Interventions

OTHERstool and blood analysis

High throughput sequencing and quantitative PCR

Study design

Allocation

NON_RANDOMIZED

Intervention model

PARALLEL

Primary purpose

SCREENING

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* PD patients : age \< or = 60 years * asymptomatic subjects : no chronic disease * asymptomatic subjects : no treatment

Exclusion criteria

* severe anemia (Hb\<7g/L) * people who don't read french * pregnant women * people treated by antibiotic, probiotic or prebiotic during the 2 month before inclusion * people with any diagnosed or treated pathology

Design outcomes

Primary

Measure	Time frame	Description
16S RNA sequencing in stool sample	2 years	16S RNA sequencing to identify species constituting the microbiota in the stool
16S RNA sequencing in blood sample	2 years	16S RNA sequencing to identify species constituting the microbiota in the blood
Stool quantification of key bacteria associated with intestinal barrier permeability.	2 years	To determine stool rates of Faecalibacterium prausnitzii, Akkermansia muciniphila, Bacteroides fragilis, Clostridium difficile, Mycobacterium avium paratuberculosis and Escherischia coli by qPCR
Blood quantification of key bacteria associated with intestinal barrier permeability.	2 years	To determine blood rates of Faecalibacterium prausnitzii, Akkermansia muciniphila, Bacteroides fragilis, Clostridium difficile, Mycobacterium avium paratuberculosis and Escherischia coli by qPCR

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026